AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38843272 — intervention group
Group type: EXPERIMENTAL
Intervention: pool-REST (weekly 1-hour float sessions)
Number of subjects: 75
Study 38843272 — intervention group
Group type: EXPERIMENTAL
Intervention: pool-REST preferred (flexible duration and frequency)
Number of subjects: 75
Study 38843272 — intervention group
Group type: COMPARATOR
Intervention: chair-REST (weekly 1-hour sessions in a Zero Gravity chair)
Number of subjects: 75
Study 38843272 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 75
Study 38843355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib (anti-IDH1 therapy)
Number of subjects: 0
Study 38843355 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapeutics
Number of subjects: 0
Study 38843469 — intervention group
Group type: EXPERIMENTAL
Intervention: nal-IRI/FU/LV
Number of subjects: 91
Study 38843469 — intervention group
Group type: COMPARATOR
Intervention: G/C
Number of subjects: 91
Study 38843479 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp cooling
Number of subjects: 139
Study 38843479 — intervention group
Group type: COMPARATOR
Intervention: Control (usual clinical practice)
Number of subjects: 139
Study 38843483 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning-based algorithm for automated treatment response assessment according to the Lugano 2014 classification.
Number of subjects: 3
Study 38843483 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning-based algorithm for automated treatment response assessment.
Number of subjects: 3
Study 38843483 — intervention group
Group type: COMPARATOR
Intervention: Radiologist review of the algorithm's assessments.
Number of subjects: 3
Study 38843488 — intervention group
Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin (Teliso-V)
Number of subjects: 172
Study 38843489 — intervention group
Group type: EXPERIMENTAL
Intervention: Subscalp EEG
Number of subjects: 8
Study 38843498 — intervention group
Group type: EXPERIMENTAL
Intervention: PRODIGY high risk group
Number of subjects: 87
Study 38843498 — intervention group
Group type: EXPERIMENTAL
Intervention: PRODIGY intermediate risk group
Number of subjects: 87
Study 38843498 — intervention group
Group type: EXPERIMENTAL
Intervention: PRODIGY low risk group
Number of subjects: 87
Study 38843498 — intervention group
Group type: COMPARATOR
Intervention: Comparison of RDE rates
Number of subjects: 87
Study 38843511 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) - 10 mg/kg intravenous infusion on days 1 and 8
Number of subjects: 603
Study 38843511 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel - 75 mg/m²
Number of subjects: 603
Study 38843513 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based single-session Empowered Relief
Number of subjects: 45
Study 38843595 — intervention group
Group type: EXPERIMENTAL
Intervention: AD + IID (30-min session)
Number of subjects: 17
Study 38843595 — intervention group
Group type: COMPARATOR
Intervention: AD alone (30-min session)
Number of subjects: 17
Study 38843604 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone assessment at 16 months
Number of subjects: 478
Study 38843604 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients asymptomatic at four months
Number of subjects: 478
Study 38843604 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients evaluated twice (4 months and 16 months)
Number of subjects: 478
Study 38843604 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety prevalence
Number of subjects: 478
Study 38843604 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung CT-scan at 16 months
Number of subjects: 478
Study 38843852 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine injury prediction rule applied to children with risk factors for cervical spine injury
Number of subjects: 22430
Study 38843852 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical algorithm for determining which risk factors warrant radiographic screening
Number of subjects: 22430
Study 38843856 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Gy radiotherapy
Number of subjects: 24
Study 38843856 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Gy radiotherapy (for those with partial response)
Number of subjects: 24
Study 38843860 — intervention group
Group type: EXPERIMENTAL
Intervention: Vimseltinib (30 mg orally twice weekly for 24 weeks)
Number of subjects: 123
Study 38843860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 38843860 — intervention group
Group type: EXPERIMENTAL
Intervention: Vimseltinib
Number of subjects: 123
Study 38843950 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) administered into the large intestine (LI)
Number of subjects: 171
Study 38843950 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) administered into the small intestine (SI)
Number of subjects: 171
Study 38843950 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) administered into the small intestine (SI) twice (repeated SI)
Number of subjects: 171
Study 38844004 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy
Number of subjects: 0
Study 38844004 — intervention group
Group type: COMPARATOR
Intervention: FF/VI
Number of subjects: 0
Study 38844004 — intervention group
Group type: COMPARATOR
Intervention: UMEC/VI
Number of subjects: 0
Study 38844374 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 µg thrice daily for 2 months
Number of subjects: 50
Study 38844374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 38844401 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser closure
Number of subjects: 56
Study 38844401 — intervention group
Group type: COMPARATOR
Intervention: Ligation of the intersphincteric fistula tract (LIFT)
Number of subjects: 56
Study 38844401 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 56
Study 38844406 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab (5 μg/m²)
Number of subjects: 177
Study 38844468 — intervention group
Group type: EXPERIMENTAL
Intervention: penpulimab and anlotinib in combination with nab-paclitaxel/gemcitabine (PAAG)
Number of subjects: 66
Study 38844602 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Leg Raising (PLR)
Number of subjects: 27
Study 38844671 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss Maintenance 3 Phases Program (WLM3P)
Number of subjects: 112
Study 38844671 — intervention group
Group type: COMPARATOR
Intervention: Standard low-carbohydrate diet (LCD)
Number of subjects: 112
Study 38844682 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab every 4 weeks (Q4W)
Number of subjects: 493
Study 38844682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study 38844793 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation (auditory stimuli delivered at specific phases of participants' alpha oscillations for 30 minutes)
Number of subjects: 21
Study 38844793 — intervention group
Group type: COMPARATOR
Intervention: Sham (headband silently recorded EEG)
Number of subjects: 21
Study 38844794 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical cretostimogene with systemic pembrolizumab
Number of subjects: 35
Study 38844796 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision-guided treatment (PGT)
Number of subjects: 384
Study 38844797 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 0
Study 38844797 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care or placebo)
Number of subjects: 0
Study 38844798 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibrated blood-collection drape for early detection of PPH and bundled first-response treatments (uterine massage, oxytocic drugs, tranexamic acid, intravenous fluids, examination and escalation)
Number of subjects: 210132
Study 38844798 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 210132
Study 38844862 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg daily for 10 weeks
Number of subjects: 10
Study 38844862 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment observation
Number of subjects: 10
Study 38844921 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual systemic anti-pseudomonal antibiotics for 14 days
Number of subjects: 49
Study 38844921 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic treatment)
Number of subjects: 49
Study 38844941 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg or 10 mg)
Number of subjects: 574
Study 38844941 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg)
Number of subjects: 574
Study 38844941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 574
Study 38844992 — intervention group
Group type: EXPERIMENTAL
Intervention: TASKPEN multifaceted implementation strategy
Number of subjects: 0
Study 38844992 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38845045 — intervention group
Group type: EXPERIMENTAL
Intervention: VHW-led lifestyle counseling and guideline-directed antihypertensive, lipid-lowering, and antiplatelet treatment supported by a tablet-based decision support application in intervention villages.
Number of subjects: 1447
Study 38845045 — intervention group
Group type: COMPARATOR
Intervention: Control group referred to a health facility for therapeutic management.
Number of subjects: 1447
Study 38845046 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06835375 (dose range: 0.03-6 mg) - single doses administered intravenously
Number of subjects: 73
Study 38845046 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06835375 (dose range: 0.3-10 mg) - repeat doses administered subcutaneously on Days 1 and 29
Number of subjects: 73
Study 38845046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 38845066 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially cardiotoxic chemotherapy (doxorubicin, cyclophosphamide, paclitaxel, trastuzumab)
Number of subjects: 210
Study 38845164 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT cut-off 20 µg/g
Number of subjects: 3841
Study 38845164 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT cut-off 40 µg/g
Number of subjects: 3841
Study 38845164 — intervention group
Group type: COMPARATOR
Intervention: FIT cut-off 10 µg/g
Number of subjects: 3841
Study 38845164 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT cut-off 20 µg/g (men)
Number of subjects: 3841
Study 38845164 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT cut-off 20 µg/g (women)
Number of subjects: 3841
Study 38845167 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma YKL-40 concentration measured before EVT
Number of subjects: 120
Study 38845180 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) plus best medical management
Number of subjects: 530
Study 38845180 — intervention group
Group type: COMPARATOR
Intervention: Best medical management only
Number of subjects: 530
Study 38845190 — intervention group
Group type: EXPERIMENTAL
Intervention: DUOSTIM fresh (double stimulation)
Number of subjects: 120
Study 38845190 — intervention group
Group type: COMPARATOR
Intervention: Single stimulation (control)
Number of subjects: 120
Study 38845190 — intervention group
Group type: EXPERIMENTAL
Intervention: DUOSTIM fresh (luteal-phase)
Number of subjects: 120
Study 38845190 — intervention group
Group type: EXPERIMENTAL
Intervention: DUOSTIM fresh (follicular-phase)
Number of subjects: 120
Study 38845288 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal treatment of traditional cardiovascular risk factors
Number of subjects: 15773
Study 38845288 — intervention group
Group type: COMPARATOR
Intervention: Prior cardiovascular disease (CVD)
Number of subjects: 15773
Study 38845288 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of risk factors outside target
Number of subjects: 15773
Study 38845288 — intervention group
Group type: EXPERIMENTAL
Intervention: Overtreated patients (haemoglobin A1c)
Number of subjects: 15773
Study 38846367 — intervention group
Group type: EXPERIMENTAL
Intervention: team-based virtual care
Number of subjects: 64
Study 38846367 — intervention group
Group type: COMPARATOR
Intervention: in-person physical therapist assessment
Number of subjects: 64
Study 38846367 — intervention group
Group type: COMPARATOR
Intervention: nurse practitioner care
Number of subjects: 64
Study 38846444 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW) intervention for 3 months
Number of subjects: 0
Study 38846444 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 0
Study 38846444 — intervention group
Group type: COMPARATOR
Intervention: Cardiological counseling (control group)
Number of subjects: 0
Study 38846451 — intervention group
Group type: EXPERIMENTAL
Intervention: PBP + Leu
Number of subjects: 0
Study 38846451 — intervention group
Group type: EXPERIMENTAL
Intervention: WHEY
Number of subjects: 0
Study 38846451 — intervention group
Group type: COMPARATOR
Intervention: PBP
Number of subjects: 0
Study 38846687 — intervention group
Group type: EXPERIMENTAL
Intervention: NTCI (cSN50.1 peptide)
Number of subjects: 0
Study 38846711 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-lowering medications
Number of subjects: 0
Study 38846711 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38846755 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 211
Study 38846755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 38846918 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 264
Study 38846918 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 264
Study 38847087 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab ± tadalafil
Number of subjects: 113
Study 38847087 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab ± BMS986205
Number of subjects: 113
Study 38847087 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab ± metformin
Number of subjects: 113
Study 38847097 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP of 77 mm Hg
Number of subjects: 134
Study 38847097 — intervention group
Group type: COMPARATOR
Intervention: MAP of 63 mm Hg
Number of subjects: 134
Study 38847281 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir-lamivudine-dolutegravir
Number of subjects: 2832
Study 38847281 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-switching)
Number of subjects: 2832
Study 38847412 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 50
Study 38847412 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium 0.9 mg/kg
Number of subjects: 50
Study 38847412 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.3 mg/kg
Number of subjects: 50
Study 38847460 — intervention group
Group type: EXPERIMENTAL
Intervention: Survodutide 2.4 mg
Number of subjects: 293
Study 38847460 — intervention group
Group type: EXPERIMENTAL
Intervention: Survodutide 4.8 mg
Number of subjects: 293
Study 38847460 — intervention group
Group type: EXPERIMENTAL
Intervention: Survodutide 6.0 mg
Number of subjects: 293
Study 38847460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study 38847538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal colonization by carbapenem-resistant Gram-negative bacteria (CR-GNB)
Number of subjects: 4641
Study 38847538 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbapenem-resistant Gram-negative bacteria (CR-GNB)
Number of subjects: 4641
Study 38847615 — intervention group
Group type: EXPERIMENTAL
Intervention: MBI-guided biopsy
Number of subjects: 21
Study 38847658 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hole clock model
Number of subjects: 43
Study 38847658 — intervention group
Group type: COMPARATOR
Intervention: Standard multimedia learning
Number of subjects: 43
Study 38847714 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago exercise program (OEP)
Number of subjects: 30
Study 38847714 — intervention group
Group type: COMPARATOR
Intervention: Gaze stability exercises (GSE)
Number of subjects: 30
Study 38847771 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative blood salvage and autotransfusion (IBSA)
Number of subjects: 6525
Study 38847766 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency surgical management of complicated colorectal cancer
Number of subjects: 240
Study 38847766 — intervention group
Group type: EXPERIMENTAL
Intervention: Management strategies for elderly patients with obstructed or perforated colorectal cancer
Number of subjects: 240
Study 38847929 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-A (MAF + biocomplex of autologous clinical-grade alveolar bone-marrow mesenchymal stem cells in collagen scaffolds enriched with aFPL)
Number of subjects: 27
Study 38847929 — intervention group
Group type: COMPARATOR
Intervention: Group-B (MAF + collagen scaffolds enriched with aFPL)
Number of subjects: 27
Study 38847929 — intervention group
Group type: COMPARATOR
Intervention: Group-C (MAF surgery alone)
Number of subjects: 27
Study 38847979 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcision with suction
Number of subjects: 154
Study 38847979 — intervention group
Group type: COMPARATOR
Intervention: Subcision alone
Number of subjects: 154
Study 38848065 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-facing preventive care reminders, electronic health record-integrated shared decision-making tool, narrative LCS guidance in LDCT ordering screen (Period 1)
Number of subjects: 1865
Study 38848065 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-facing reminders for LCS discussion and LCS (Period 2)
Number of subjects: 1865
Study 38848065 — intervention group
Group type: COMPARATOR
Intervention: Baseline period (Control)
Number of subjects: 1865
Study 38848065 — intervention group
Group type: EXPERIMENTAL
Intervention: Period 2 (Post-intervention)
Number of subjects: 1865
Study 38848067 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended telephone coaching (12 calls during weeks 5-16)
Number of subjects: 437
Study 38848067 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief telephone coaching (3 calls during weeks 5-8)
Number of subjects: 437
Study 38848067 — intervention group
Group type: COMPARATOR
Intervention: No coaching (control)
Number of subjects: 437
Study 38848312 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent mRNA SARS-CoV-2 vaccines (mRNA-1273.214 or BA.1-adapted BNT162b2)
Number of subjects: 172
Study 38848380 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led interprofessional medication adherence program (IMAP) for 12 months
Number of subjects: 118
Study 38848380 — intervention group
Group type: COMPARATOR
Intervention: Standard care plus electronic monitors (EM) without intervention
Number of subjects: 118
Study 38848400 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples Health CoOp Plus (CHC+) intervention
Number of subjects: 480
Study 38848400 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigma awareness and education workshop
Number of subjects: 480
Study 38848400 — intervention group
Group type: EXPERIMENTAL
Intervention: CHC+ and stigma awareness workshop interaction
Number of subjects: 480
Study 38848477 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir-ritonavir (NMV/r, 300 mg and 100 mg)
Number of subjects: 155
Study 38848477 — intervention group
Group type: COMPARATOR
Intervention: Placebo-ritonavir (PBO/r)
Number of subjects: 155
Study 38848477 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir-ritonavir (NMV/r)
Number of subjects: 155
Study 38848522 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cetirizine
Number of subjects: 395
Study 38848522 — intervention group
Group type: COMPARATOR
Intervention: Intravenous clemastine
Number of subjects: 395
Study 38848521 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrectinib
Number of subjects: 12
Study 38848521 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial cfDNA monitoring
Number of subjects: 12
Study 38848537 — intervention group
Group type: EXPERIMENTAL
Intervention: NGS-based classifier for T-ALL
Number of subjects: 440
Study 38848537 — intervention group
Group type: EXPERIMENTAL
Intervention: NGS-based classifier combined with WBC count and MRD
Number of subjects: 440
Study 38848557 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based morning and evening messages based on current readiness to quit smoking.
Number of subjects: 152
Study 38848557 — intervention group
Group type: COMPARATOR
Intervention: Control group received 2 daily messages unrelated to smoking.
Number of subjects: 152
Study 38848742 — intervention group
Group type: EXPERIMENTAL
Intervention: MesoPher (dendritic cells loaded with allogeneic tumour cell lysate)
Number of subjects: 176
Study 38848742 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care alone
Number of subjects: 176
Study 38848742 — intervention group
Group type: EXPERIMENTAL
Intervention: MesoPher
Number of subjects: 176
Study 38848742 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 176
Study 38849054 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated low-level red light therapy (RLRL) plus single-vision spectacles
Number of subjects: 192
Study 38849054 — intervention group
Group type: COMPARATOR
Intervention: Single-vision spectacles (control)
Number of subjects: 192
Study 38849054 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated low-level red light therapy (RLRL)
Number of subjects: 192
Study 38849152 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg two times per day or equivalent weight-based doses
Number of subjects: 225
Study 38849152 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib
Number of subjects: 225
Study 38849283 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus pomalidomide/dexamethasone (NPd)
Number of subjects: 300
Study 38849283 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab, pomalidomide/dexamethasone, and elotuzumab (NE-Pd)
Number of subjects: 300
Study 38849283 — intervention group
Group type: COMPARATOR
Intervention: Pomalidomide/dexamethasone (Pd)
Number of subjects: 300
Study 38849344 — intervention group
Group type: EXPERIMENTAL
Intervention: Amp1q
Number of subjects: 400
Study 38849344 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain1q
Number of subjects: 400
Study 38849344 — intervention group
Group type: COMPARATOR
Intervention: Normal 1q
Number of subjects: 400